Moderna, Inc. $MRNA Shares Sold by Profund Advisors LLC

Profund Advisors LLC decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 39.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,994 shares of the company’s stock after selling 13,148 shares during the quarter. Profund Advisors LLC’s holdings in Moderna were worth $3,850,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. ProShare Advisors LLC grew its stake in shares of Moderna by 6.1% during the third quarter. ProShare Advisors LLC now owns 74,898 shares of the company’s stock valued at $14,423,000 after purchasing an additional 4,277 shares during the last quarter. Vise Technologies Inc. raised its stake in shares of Moderna by 63.0% in the 3rd quarter. Vise Technologies Inc. now owns 8,879 shares of the company’s stock valued at $1,710,000 after purchasing an additional 3,432 shares during the period. Blue Fin Capital Inc. bought a new stake in shares of Moderna in the third quarter worth $432,000. MGO One Seven LLC boosted its position in Moderna by 8.7% during the third quarter. MGO One Seven LLC now owns 3,428 shares of the company’s stock valued at $660,000 after purchasing an additional 275 shares during the last quarter. Finally, Americana Partners LLC acquired a new position in shares of Moderna during the 3rd quarter worth about $1,482,000. Institutional investors own 75.33% of the company’s stock.

Insider Activity

In related news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 over the last quarter. Insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MRNA. William Blair downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 27th. Singular Research raised shares of Moderna to a “hold” rating in a report on Wednesday, September 23rd. Bank of America raised their price objective on Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Finally, Morgan Stanley raised their price objective on Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $107.10.

Moderna Stock Down 0.5%

Moderna stock opened at $221.72 on Friday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $182.49 and its two-hundred day moving average price is $86.52. The firm has a market capitalization of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.09. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $254.48.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.13) EPS. On average, equities research analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.